ABBOTT PARK, Ill., Jan. 17, 2023 /PRNewswire/ -- Abbott (NYSE: ABT) today announced that the U.S. Food and Drug Administration (FDA) has approved the company's latest-generation transcatheter aortic ...

Navitor is now approved as a minimally invasive alternative to surgery for patients in Europe with symptomatic, severe aortic stenosis (a common and life-threatening heart valve disease) who are at ...

After Boston Scientific retired its entire line of Lotus Edge replacement heart valves late last year amid a flurry of issues with its delivery system, Abbott has stepped up to fill in the gap in the ...

Abbott Laboratories is making some noise in the transcatheter aortic repair/implantation market this week by announcing CE mark of its Navitor system. The device is minimally invasive and for people ...

- The non-surgical Navitor TAVI system offers best-in-class deliverability and access through small vessels, expanding treatment options for patients with severe aortic stenosis ABBOTT PARK, Ill., May ...

Abbott (ABT)'s new Navitor device features advancements to improve patient care, including reducing or eliminating risk of blood leakage around valve implant Transcatheter aortic valve implantation ...

Abbott Laboratories’ (NYSE: ABT) Navitor transcatheter aortic valve implantation (TAVI) system has received a CE mark, making it available in Europe to those with severe aortic stenosis and a high or ...

- Latest-generation TAVI system features advancements to reduce or eliminate risk of blood leakage around valve implant - The non-surgical Navitor TAVI system offers best-in-class deliverability and ...